Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dr. willmar schwabe gmbh & co. kg - valeriana officinalis l., root, dry extract 160 mg; melissa officinalis l., leaf, dry extract 80 mg - coated tablet - melissa officinalis, leaf, dry extract 80 mg; valeriana officinalis, root, dry extract 160 mg - hypnotics and sedatives in combination, excl. barbiturates

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoria qualiphar sa-nv - crataegus monogyna jacq. (lindm.) and-or c. laevigata (poiret) d.c., leaf & flower, dry extract - quantified, ethanol, 75, 4-6_1 25 mg; passiflora incarnata l., herb, dry extract, etoh, 60, 1-2,5_1 25 mg; valeriana officinalis l., root, dry extract - quantified, etoh, 70, 5-6_1 100 mg - capsule, hard - crataegus oxyacantha, flower, dry extract 25 mg; passiflora incarnata herb, dry extract 25 mg; valeriana officinalis, root, dry extract 100 mg - hypnotics and sedatives in combination, excl. barbiturates

Israel - English - Ministry of Health

pharma shalom - melissa officinalis; valerian dry extract - coated tablets - valerian dry extract 120 mg; melissa officinalis 80 mg - other hypnotics and sedatives - sedative in states of tension, nervousness and insomnia.

Ireland - English - HPRA (Health Products Regulatory Authority)

gr lane health products ltd - humulus lupulus ; leonurus cardiaca ; valerian dry hydroalcoholic extract ph.eur.; passiflora incarnata ; thiamine hydrochloride ; riboflavin ; nicotinamide - tablets - per cent - valerianae radix

Israel - English - Ministry of Health

pharma shalom - melissa officinalis; valerian dry extract - coated tablets - valerian dry extract 120 mg; melissa officinalis 80 mg - sedative in states of tension, nervousness and insomnia.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

minskintercaps u.v. - valerian dry extract, melissa dry extract - capsules - 0,582mg+ 2mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

gm pharmaceuticals ltd - passiflora incarnata, valeriana officinalis, hypericum perforatum, melissa officinalis, crataegus - capsules - 100mg+ 60mg+ 50mg+ 20mg+ 20mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

natural wellness industries sdn. bhd. (milik penuh nutrivention sdn. bhd) - saccharum officinarum extract; olea europaea leaf extract; nigella sativa.; commiphora mukul extract; camelia sinensis (green tea) leaf extract -

United States - English - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta er (tapentadol) is indicated for the management of: - pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate - neuropathic pain associated with diabetic peripheral neuropathy (dpn) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve nucynta er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. nucynta er is not indicated as an as-needed (prn) analgesic. - nucynta er is not indicated as an as-neede

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - nucynta er (tapentadol) is indicated for the management of: - pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate - neuropathic pain associated with diabetic peripheral neuropathy (dpn) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve nucynta er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - nucynta er is not indicated as an as-needed (prn) analgesic. nucynta er is contraindicated in patients wi